市場調查報告書
商品編碼
1383349
生理節律睡眠障礙的全球市場到2030年預測:按治療類型、藥物類型、年齡、配銷通路、應用、最終用戶和地區進行分析Circadian Rhythm Seep Disorder Market Forecasts to 2030 - Global Analysis By Treatment Type, Drug Type, Age, Distribution Channel, Application, End User and By Geography |
根據 Stratistics MRC 的資料,2023年全球生理節律睡眠障礙市場規模為 7.6187 億美元,預計到2030年將達到 11.9174 億美元,預測期內年複合成長率為 6.6%。
生理節律睡眠障礙是指晝夜節律(人體的內在手錶)出現異常的情況。與晝夜節律相關的睡眠障礙是由外在環境和中樞晝夜計時系統的變化所帶來的。如果難以按時入睡並且睡眠時間表被打亂,那麼通常患有生理節律睡眠障礙。生理節律睡眠障礙有多種類型,包括時差型、輪班工作障礙、提前睡眠相位障礙(ASPS)、延遲睡眠相位障礙(DSPD)和無規則型。
根據睡眠心臟研究,有失眠或睡眠不足史的人罹患心血管疾病(CVD)的風險增加 29%。這些數字鼓勵患有睡眠障礙的人尋求專業協助並增加市場需求。
公共衛生配合措施、教育宣傳活動以及透過數位平台普及資訊的力度加大,人們對生理節律睡眠障礙的認知不斷提高。此外,診斷率的提高是患者和醫療保健提供者對 CRSD徵兆和症狀的認知提高的結果。隨著診斷普及越來越普遍,越來越多的人尋求適當的治療和管理方案,這推動市場擴張。
CRSD 市場的一個主要障礙是缺乏對與晝夜節律相關的睡眠障礙的知識和認知。公眾和醫療專業人員可能都無法識別這些症狀或將其誤認為是其他疾病。此外,這種無知可能會導致診斷不足和治療延遲,阻礙市場擴張。
對睡眠障礙的晝夜節律、遺傳學和神經生物學的持續研究使得針對 CRSD 各種亞型的新診斷設備、治療性介入和藥物的開發成為可能。此外,這項研究是改善患者治療效果和更有效治療的關鍵。
公眾和醫療保健相關人員對這些疾病的認知較低,對 CRSD 市場構成嚴重威脅。許多患有 CRSD 的人未被診斷或誤診,並且經常將他們的症狀歸咎於其他疾病。然而,知識不足阻礙了快速診斷和有效治療。
生理節律睡眠障礙(CRSD)市場受到 COVID-19大流行的各種影響。在大流行最嚴重的時候,患者就診的減少,醫療保健服務的變化以及 COVID-19 病例的優先處理導致了 CRSD 診斷和治療的延遲。睡眠診所的暫時關閉及其運作限制影響了患者獲得治療的機會。此外,睡眠障礙的增加是由於生活方式的改變和大流行帶來的心理壓力。
燈箱細分市場在生理節律睡眠障礙市場中佔有最大佔有率。 CRSD 的重要非藥物治療之一是光療,通常透過燈箱進行。對於輪班工作睡眠障礙和睡眠時相延遲障礙等疾病尤其如此。此外,燈箱產生的明亮人造光可以透過模擬陽光來幫助重置人的晝夜節律。燈箱在臨床和家庭中廣泛使用,可成功管理 CRSD 症狀。光療法廣泛應用於CRSD的治療計劃中,並且由於其非侵入性且有效,在「燈箱」類別中擁有很大的市場佔有率。
生理節律睡眠障礙(CRSD)市場預計將在健康中心和水療中心領域實現最高的年複合成長率。健康中心和水療中心擴大在其菜單中添加睡眠健康服務,包括放鬆療法和以 CRSD 為重點的治療。此外,這些設置還提供針對睡眠障礙的全面治療策略,強調放鬆和整體健康。隨著人們越來越意識到睡眠與健康之間的聯繫,他們開始轉向健康中心和水療中心尋求專業的治療和療法。
北美(包括美國和加拿大)通常佔據生理節律睡眠障礙(CRSD)的最大市場佔有率佔有率。此外,該地區完善的醫療保健體系,出色的研發工作,睡眠障礙的高發病率以及人們對睡眠健康重要性的認知不斷增強是這一優勢的主要原因。該地區由於其富裕程度和睡眠障礙發病率高而成為 CRSD 市場的領導者,使其成為睡眠醫學領域創新和發展的中心。
生理節律睡眠障礙(CRSD)市場預計將成為亞太地區最高的年複合成長率。該地區的強勁成長得益於多種因素,包括睡眠衛生意識的提高,生活方式的變化導致 CRSD 發病率的增加以及醫療設施的發展。人們對整體健康和福祉的日益重視,加上亞太地區的經濟擴張,推動對治療睡眠障礙的創新方法的需求。此外,由於都市化、醫療保健支出增加和中階擴大等因素,亞太地區 CRSD 市場經歷快速成長。因此,該市場被定位為一個充滿活力且快速擴張的細分市場,未來市場開拓備受期待。
According to Stratistics MRC, the Global Circadian Rhythm Seep Disorder Market is accounted for $761.87 million in 2023 and is expected to reach $1191.74 million by 2030 growing at a CAGR of 6.6% during the forecast period. The term circadian rhythm sleep disorders (CRSDs) refers to conditions where the body's internal clock, the circadian rhythms, are abnormal. Sleep disorders related to the circadian rhythm are brought on by changes in the external environment and the central circadian timekeeping system. When a person struggles to go to sleep at a regular time and interferes with their sleep schedule, they usually have circadian rhythm sleep disorders. And, there are various types of circadian rhythm sleep disorders, including jet lag, shift work disorder, advanced sleep phase disorder (ASPS), delayed sleep phase disorder (DSPD), and the free-running type.
According to a sleep heart study, those who had a history of insomnia or poor sleep had a 29 % increased risk of cardiovascular disease (CVD). These kinds of figures encourage those suffering from sleep disorders to seek expert assistance, hence raising the market's demand.
Increased public health efforts, education campaigns, and the spread of information via digital platforms are all responsible for the rising awareness of circadian rhythm sleep disorders. Additionally, rising diagnosis rates are a result of patients and medical professionals' increased awareness of the telltale signs and symptoms of CRSDs. Growing numbers of people are seeking suitable treatment and management options as diagnosis becomes more widely available, which propels market expansion.
A major barrier to the CRSD market is the lack of knowledge and awareness regarding sleep disorders related to the circadian rhythm. Both the general public and medical professionals might not be aware of the symptoms or might mistake them for other illnesses. Moreover, this ignorance may result in under diagnosis and postponed treatment, impeding the expansion of the market.
The development of novel diagnostic instruments, therapeutic interventions, and pharmaceuticals specifically designed for various subtypes of CRSDs is made possible by ongoing research into circadian rhythms, genetics, and the neurobiology of sleep disorders. Additionally, this study holds the key to improved patient outcomes and more potent treatments.
The low awareness of these disorders among the general public and medical professionals poses a serious threat to the CRSD market. Many people with CRSDs go undiagnosed or are misdiagnosed, and they frequently blame their symptoms on other medical conditions. However, inadequate knowledge impedes prompt diagnosis and efficient therapy.
The Circadian Rhythm Sleep Disorder (CRSD) market was impacted by the COVID-19 pandemic in a number of ways. Delays in diagnosing and treating CRSDs occurred during the height of the pandemic due to decreased patient visits, changes in healthcare services, and the prioritization of COVID-19 cases. Patient access to care was impacted by the temporary closure of sleep clinics and the implementation of restrictions on their operations. Additionally, a rise in sleep disorders was attributed to changes in lifestyle and psychological stress brought on by the pandemic.
In the market for circadian rhythm sleep disorders, the Light Box segment has the largest share. One important non-pharmacological treatment for CRSDs is light therapy, which is frequently given through light boxes. This is especially true for disorders like shift work sleeps disorder and delayed sleep phase disorder. Moreover, bright artificial light produced by light boxes can help reset a person's circadian rhythms by simulating sunlight. They are extensively utilized to successfully manage CRSD symptoms in both clinical and domestic contexts. Because light therapy is widely used in CRSD treatment plans and is both non-invasive and effective, it has a significant market share in the "Light Box" category.
The Circadian Rhythm Sleep Disorder (CRSD) market is expected to grow at the highest CAGR in the Wellness Centers & Spa segment. A growing number of wellness centers and spas are adding sleep health services to their menus, such as relaxation therapies and CRSD-focused treatments. Additionally, these environments offer a comprehensive strategy for treating sleep disorders, emphasizing relaxation and general well-being. People are going to wellness centers and spas for specialized treatments and therapies as awareness of the link between sleep and wellbeing increases.
In terms of market share for Circadian Rhythm Sleep Disorder (CRSD), North America, which includes the United States and Canada, usually has the largest share. Moreover, the region's established healthcare system, prodigious R&D endeavours, high incidence of sleep disorders, and growing consciousness regarding the importance of sleep health are the main causes of this dominance. Due to its high level of affluence and high rate of sleep disorders, the region leads the CRSD market and serves as a hub for innovations and developments in the field of sleep medicine.
In the Circadian Rhythm Sleep Disorder (CRSD) market, the Asia-Pacific region is projected to have the highest CAGR. The region's strong growth is ascribed to various factors, including growing consciousness regarding sleep hygiene, the increasing occurrence of CRSDs as a result of evolving lifestyles, and the development of healthcare facilities. A greater emphasis on general health and well-being, coupled with the expansion of economies in the Asia-Pacific region, is driving demand for creative approaches to sleep disorders. Additionally, the Asia-Pacific CRSD market has experienced rapid growth due to factors such as urbanization, rising healthcare expenditures, and the region's expanding middle class. This has positioned the market as a dynamic and rapidly expanding segment with significant potential for future development.
Some of the key players in Circadian Rhythm Seep Disorder market include: Carex Health, The Sunbox Company, Garmin Ltd., BMC Medical Co., Ltd, Teva Pharmaceutical Industries Ltd., Natus Medical Incorporated , Koninklijke Philips N.V., Mylan N.V., Vanda Pharmaceuticals Inc., Neuraxpharm, Sunrise System , Beurer GmbH, Lanaform N.V., Samarit Medical AG, Takeda Pharmaceutical Company, Northern Light Technologies , RedMed Inc. , ActiGraph, LLC, Verilux, Inc. and Akeda Pharmaceutical Company Limited .
In August 2023, Garmin Ltd., announced it has entered into a definitive agreement to acquire JL Audio, a privately-held U.S. company that designs and manufactures audio solutions for marine, aftermarket automotive, powersports, home and RV customers.
In July 2023, Teva Pharmaceuticals, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd., and Alvotech, a global biotech company specializing in the development and manufacture of biosimilars, expanded their existing strategic partnership agreement. Teva will also acquire subordinated convertible bonds to be issued by Alvotech.
In December 2022, Natus Medical announced that it entered into a definitive agreement to acquire neurophysiology solution provider Micromed. Middleton, Wisconsin-based Natus expects the transaction to close in early 2023. The company elected not to disclose the financial terms of the deal. It marks the first transaction made by the company since its $1.2 billion acquisition by the ArchiMed group in July.
Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.